Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed outlook. While there are positive signs such as margin expansion, strong biologics growth, and strategic capacity investments, there are also concerns about slower order materialization in the Engineering segment, inflationary pressures, and a lack of clarity in management's responses. The lack of new partnerships or significant shareholder return plans, along with no clear guidance changes, suggests a neutral sentiment. Without market cap data, the prediction remains neutral, assuming average volatility.
Key Financial Performance
Revenue Growth 10% revenue growth on a constant currency basis in Q1 2026 compared to Q1 2025, driven by strong growth in the Biopharmaceutical and Diagnostic Solutions segment, particularly pre-fillable syringes which increased over 20% year-over-year.
Revenue from High-Value Solutions Revenue from high-value solutions increased 17% to EUR 128.6 million in Q1 2026, accounting for 47% of total revenue. Growth was driven by high-value syringes and EZ-fill vials.
Revenue from Biologics Revenue from biologics increased 15% in Q1 2026, driven by GLP1s which accounted for approximately 21%-22% of total company revenue. Growth was supported by demand for ready-to-use and bulk cartridges.
Gross Profit Margin Gross profit margin increased 30 basis points to 27.5% in Q1 2026, driven by improvements in facilities in Latina and Fishers, an increase in high-value solutions, and improved marginality in the Engineering segment. However, higher depreciation and foreign currency effects partially offset these gains.
Operating Profit Margin Operating profit margin increased 70 basis points to 14.2% in Q1 2026, and adjusted operating profit margin rose 60 basis points to 14.9%. This was due to operational improvements and a favorable mix of high-value solutions.
Net Profit Net profit totaled EUR 28 million in Q1 2026, with adjusted net profit increasing 5% to EUR 29.6 million. Adjusted diluted EPS grew 10% to EUR 0.11.
Adjusted EBITDA Adjusted EBITDA increased 14% to EUR 65.5 million in Q1 2026, with an adjusted EBITDA margin increase of 150 basis points to 23.9%.
BDS Segment Revenue Revenue from the BDS Segment increased 16% at constant currency and 13% on a reported basis to EUR 249 million in Q1 2026. Growth was driven by high-value syringes and other product categories.
Engineering Segment Revenue Revenue from the Engineering segment decreased 31% to EUR 24.6 million in Q1 2026, due to lower sales from assembly and glass conversion. However, gross profit margin improved 460 basis points to 15.3% due to operational efficiencies.
Capital Expenditures Capital expenditures totaled EUR 67.6 million in Q1 2026, with over 90% related to growth investments in high-value solutions at Fishers and Latina.
Free Cash Flow Free cash flow was EUR 5.5 million in Q1 2026, with net cash from operating activities totaling EUR 75.5 million and cash used in property, plant, and equipment, and intangible assets amounting to EUR 70.7 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Pre-fillable syringes: Ongoing demand for pre-fillable syringes contributed to 20% year-over-year growth in this category. New capacity was brought into service in plants in Latina and Fishers.
Cartridges and vials: Growing demand for cartridges, especially for biologics like monoclonal antibodies, with a shift towards home-based solutions and subcutaneous injections. Conversion of a vial line to a cartridge line in Piombino Dese to meet demand.
GLP1s and incretin therapies: GLP1s accounted for 21%-22% of total revenue, driving a 15% increase in revenue from biologics. Market expected to grow with novel indications and biosimilars gaining traction.
Injectable biologics: Strong growth trajectory expected, driven by biosimilars, monoclonal antibodies, and advanced therapies. Demand for high-value solutions continues to rise.
Engineering segment optimization: Improved margins due to operational efficiency and right-sizing efforts, particularly in Denmark. Focus on sales and marketing to drive growth.
Capacity expansion: Scaling growth investments in Fishers and Latina with high-speed RTU cartridge lines and device assembly areas. Commercial production expected by 2027.
Shift to high-value solutions: De-emphasizing non-core products in favor of high-value solutions like large batch Not for Human Use fill and finish services.
Global footprint optimization: Maximizing operational flexibility and aligning capital investments with market demand to maintain competitive position in injectables market.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Engineering Segment Revenue Decline: The Engineering segment experienced a 31% revenue decline due to lower sales from assembly and glass conversion, coupled with a slow pace of new order intake and a low backlog. This poses a risk to financial performance and operational sustainability.
Customer Order Delays: Customer orders in the Engineering segment are materializing slower than expected, which could impact revenue growth and backlog replenishment.
Higher Depreciation Costs: Higher depreciation costs related to ramp-ups in Fishers and Latina facilities are offsetting some of the financial gains from operational improvements.
Foreign Currency Headwinds: Foreign currency fluctuations negatively impacted gross profit margins, creating financial uncertainty.
Tariffs Impact: Tariffs have negatively impacted financial performance, with some recovery expected in future periods but not guaranteed.
Discontinued Tax Incentive: The discontinuation of the IRES Premiale tax incentive in Italy has increased the company's tax rate, reducing net profitability.
Operational Challenges in Engineering Segment: Despite margin improvements, the Engineering segment faces challenges due to low backlog and the time required to secure new orders, which could delay financial recovery.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company maintains its 2026 revenue guidance in the range of EUR 1.260 billion to EUR 1.290 billion.
Adjusted EBITDA and EPS Guidance for 2026: Adjusted EBITDA is expected to be between EUR 331.8 million and EUR 346.9 million, and adjusted diluted EPS is projected to range from EUR 0.59 to EUR 0.63.
Growth in Biologics and Injectable Therapies: The company anticipates a strong growth trajectory for the injectable biologics market over the coming years, driven by biosimilars, monoclonal antibodies, and other advanced therapies.
Expansion Projects in Fishers and Latina: Commercial production at the Fishers site is expected to begin at the end of 2026 or early 2027. The Latina site will launch commercial production of RTU cartridges on new high-speed lines in early 2027.
Market Trends in GLP1s and Biologics: The market for GLP1s and incretin therapies is expected to grow over the next decade, with novel indications beyond diabetes and obesity, and biosimilars gaining traction. Demand for cartridges for biologics, including monoclonal antibodies, is also increasing.
Engineering Segment Outlook: The company is cautious about the Engineering segment due to a low backlog and slow pace of new orders but is focused on improving operational efficiency and rebuilding the backlog.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are you thinking about volume visibility and durability of GLP1s, and how should investors frame the risk from orals over time?
A:The GLP market is expected to grow over the next several years, with predictable volumes due to contractual commitments. GLPs represent a durable tailwind, with 70% of the market opportunity in injectables and 30% in orals. Early data suggests market expansion rather than cannibalization of injectables. The market opportunity is significant, with over 150 million potential patients in the U.S. and 1.5 billion globally for obesity and diabetes.
Q:Can you provide an update on the Annex 1 program and quantify the tailwind from that?
A:Annex 1 is seen as a long-term accelerator to ready-to-use (RTU) adoption, simplifying regulatory compliance for customers. It specifies higher standards for contamination control and quality risk management. The transition from bulk to RTU is driven by multiple factors, and the program is expected to provide a tailwind over time.
Q:Can you talk about the moving parts in the BDS segment margins in the first quarter and provide color on GPM for the BDS segment for the year?
A:BDS gross profit margin is expected to be in line or slightly better than last year. Positive factors include a better mix, while pressures include depreciation and currency headwinds (EUR 18 million impact). In Q1, depreciation impacted EUR 4 million, currency headwinds EUR 8 million, and temporary tariffs in the Middle East also affected margins. Overall, margins are expected to grow consistently or slightly better than 2025.
Q:Is the fill and finish services, Not for Human Use, considered a high-value solution, and how do the margins compare to your 40%-47% gross profit margin range for HVS?
A:Yes, it is considered a high-value solution with very accretive margins within the high-value solution range. Overall gross profit margin expanded by 30 basis points compared to the same period last year, and adjusted EBITDA margin expanded by 150 basis points, in line with the annual guidance.
Q:Can you talk about the Engineering segment, the slower materialization of orders, and visibility into recovery?
A:Operational improvements in on-time delivery, cost structure, and manufacturing footprint are delivering margin expansion. The focus is on winning new contracts, with stronger performance expected in the second half of the year. Demand is strong in visual inspection machines and assembly/packaging for self-administration. The sales cycle has lengthened due to more disciplined procurement and higher hurdles for capital investments by customers.
Q:Can you provide guidance for Q2 revenue, margins, and earnings, and discuss margin progression through the year?
A:The first half of the year is expected to represent 45% of annual revenue. Q2 growth is anticipated to be high single-digit to low double-digit in the BDS segment, with a 10% decline in Engineering compared to last year. High-value solutions are expected to represent 47%-48% of revenue for the year. The second half of the year is expected to be stronger than the first half.
Q:Why is the biologics business growing at 15% when the market is at 10%?
A:GLPs are a significant driver of biologics growth, along with revenues from mAbs, biosimilars, mRNA applications, and other therapeutic areas. Demand is concentrated in pre-fillable syringes, with increasing prospects in cartridges. The ramp-up of additional capacity in Fishers is also contributing to mid-teens growth.
Q:Is the assembly Denmark project complete, and should the higher gross margin level continue?
A:Yes, the assembly Denmark project is complete, and the project mix has improved profitability. The guidance for EUR 130-140 million third-party revenue in Engineering reflects a more selective approach to large, complex, customized projects. Margin expansion compared to 2025 is expected to continue.
Q:Can you confirm that the current lag in Engineering is due to sales cycle extension and not losing share or increased competition?
A:Yes, the lag is due to longer decision cycles by customers, with more disciplined procurement and higher hurdles for capital investments. The company has been adding talent in Engineering to strengthen the team, particularly in the U.S., and is not losing share or facing increased competition.
Q:What is the current status of cartridge demand and capacity expansion?
A:Cartridge demand is accelerating, with the company fully booked for 2026. A converted line in Piombino Dese is set to begin service by the end of Q2 2026, and additional capacity is being installed in Latina for large volumes and competitive contracts. The company is well-positioned to capture future demand driven by innovation in large-volume drug containment.
Q:Can you disaggregate GLP1 versus non-GLP1 growth within Q1 HVS?
A:GLP1 represented 21%-22% of revenue in Q1, growing slightly more than 20% compared to last year. Non-GLP1 biologics grew mid-single digits (6%). Both segments are growing, with capacity playing a role in addressing customer needs.
Q:Did inflationary pressures impact Q1, and how is this considered in guidance?
A:Inflationary pressures, including higher gas, energy, and logistics costs, have been mitigated through discussions with customers to adjust prices. The company has taken actions to avoid P&L impact, similar to its response to gas price increases in 2022. These factors are embedded in the guidance.
Q:Was there anything surprising regarding margins in Q1?
A:No surprises were reported. Temporary tariffs impacted EUR 1.7 million, while depreciation and exchange rate effects were in line with expectations and embedded in the model for future periods.
Q:What are the dynamics in EZ-fill vials and cartridges, and is there under-utilization after the conversion?
A:EZ-fill vials grew significantly in Q1, with overall vials up mid-single digits. Cartridge demand is growing more rapidly, leading to the conversion of a vial line to cartridges. Some under-utilization exists in certain regional pockets for vials, but overall demand is growing.
Q:Could there be a need for further investment in cartridge capacity beyond current plans?
A:At the moment, the company is focused on completing the RTU 400 lines in Latina and has no immediate plans for further investment. The converted line in Piombino Dese is set to begin service by the end of Q2 2026, addressing current demand.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about the typical lag between Site Acceptance Tests (SATs) and revenue recognition in the Engineering segment. While they explained the revenue recognition process (percentage of completion method), they did not provide a clear timeline or quantify the lag between SATs and revenue realization.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Communications
GLPs
Latina Fishers
RTU
Segment
Today
action
backlog
biologics
capacity service
cartridge capacity
customer validation
delivery
demand trend
development
driver
drug
expectation
improvement segment
investment
line
market
ml
momentum
optimization plan
order
pharma
phase
production
project
segment demand
shift
solution
traction
use cartridge
value
volume
STVN Transcript
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals a mixed outlook. While there are positive signs such as margin expansion, strong biologics growth, and strategic capacity investments, there are also concerns about slower order materialization in the Engineering segment, inflationary pressures, and a lack of clarity in management's responses. The lack of new partnerships or significant shareholder return plans, along with no clear guidance changes, suggests a neutral sentiment. Without market cap data, the prediction remains neutral, assuming average volatility.
Stevanato Group S.p.A. (STVN) Q4 2025 Earnings Call Transcript
Positive3-4
The company reported a strong financial performance with a 15% revenue increase, improved gross margins, and a 25% rise in free cash flow. Despite regulatory risks, the positive financial metrics and optimistic guidance on capital projects and market trends suggest a favorable outlook. No negative sentiment from the Q&A was noted. Given these factors, the stock price is likely to experience a positive movement in the short term.
Stevanato Group S.p.A. (STVN) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call reveals strong demand for high-value products, robust growth projections, and a resilient financial position despite FX headwinds and engineering delays. Management's optimistic guidance and strategic focus on capacity expansion and product innovation indicate positive sentiment. Although some uncertainties exist, particularly in the Engineering segment, the overall outlook supports a positive stock price movement.
STVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
